Beam Therapeutics (BEAM) Long-Term Investments (2020 - 2021)
Beam Therapeutics (BEAM) posted quarterly Long-Term Investments of $24.5 million for Q3 2021, down 16.62% quarter-over-quarter from $29.4 million in Q2 2021.
Powered by 
Analysis
Beam Therapeutics (BEAM) Long-Term Investments (2020 - 2021) Analysis & Trends
Beam Therapeutics (BEAM) has reported Long-Term Investments for 2 consecutive years, with $24.5 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Long-Term Investments changed N/A year-over-year to $24.5 million; the TTM figure through Sep 2021 stood at $24.5 million (changed N/A YoY), while the FY2020 annual figure was $2.6 million, changed N/A from the prior year.
- Long-Term Investments fell to $24.5 million in Q3 2021 per BEAM's latest filing, from $29.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $29.4 million in Q2 2021 and bottomed at $2.6 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 24.54 Mn |
| Jun 30, 2021 | 29.43 Mn |
| Dec 31, 2020 | 2.58 Mn |